...
search icon
phar-img

Pharming Group NV Share Price

PHAR
NMQ
$16.866
+$0.57
(3.5%)
1D
Industry: Biotechnology Sector: Health Care

Pharming Group NV Analyst Forecast

Pharming Group NV Share Price Chart

Pharming Group NV Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.14B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
18.65K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.5 L
$21.34 H
$16.866

About Pharming Group NV, Common Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. more

Industry: BiotechnologySector: Health Care

Pharming Group NV Stock Returns

Time FramePHARSectorS&P500
1-Week Return0.68%1.31%-1.33%
1-Month Return-9.04%1.27%0.78%
3-Month Return0.46%3.74%2.61%
6-Month Return31.56%15.81%6.19%
1-Year Return72.4%8.89%11.68%
3-Year Return47.74%19.23%67.81%
5-Year Return14.79%35.04%74.06%
10-Year Return-2.4%136.97%255.08%

Pharming Group NV Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue212.17M198.87M205.62M245.32M297.20M[{"date":"2020-12-31","value":71.39,"profit":true},{"date":"2021-12-31","value":66.91,"profit":true},{"date":"2022-12-31","value":69.19,"profit":true},{"date":"2023-12-31","value":82.54,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue23.54M21.14M17.56M25.21M35.40M[{"date":"2020-12-31","value":66.5,"profit":true},{"date":"2021-12-31","value":59.72,"profit":true},{"date":"2022-12-31","value":49.61,"profit":true},{"date":"2023-12-31","value":71.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit188.63M177.73M188.06M220.10M261.80M[{"date":"2020-12-31","value":72.05,"profit":true},{"date":"2021-12-31","value":67.89,"profit":true},{"date":"2022-12-31","value":71.83,"profit":true},{"date":"2023-12-31","value":84.07,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin88.91%89.37%91.46%89.72%88.09%[{"date":"2020-12-31","value":97.21,"profit":true},{"date":"2021-12-31","value":97.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.1,"profit":true},{"date":"2024-12-31","value":96.32,"profit":true}]
Operating Expenses112.38M164.17M169.83M225.49M270.42M[{"date":"2020-12-31","value":41.56,"profit":true},{"date":"2021-12-31","value":60.71,"profit":true},{"date":"2022-12-31","value":62.8,"profit":true},{"date":"2023-12-31","value":83.38,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income76.26M13.56M18.23M(5.39M)(8.62M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":17.78,"profit":true},{"date":"2022-12-31","value":23.91,"profit":true},{"date":"2023-12-31","value":-7.06,"profit":false},{"date":"2024-12-31","value":-11.31,"profit":false}]
Total Non-Operating Income/Expense(36.80M)16.86M(4.22M)(9.06M)(4.96M)[{"date":"2020-12-31","value":-218.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25.05,"profit":false},{"date":"2023-12-31","value":-53.74,"profit":false},{"date":"2024-12-31","value":-29.4,"profit":false}]
Pre-Tax Income44.09M23.08M14.99M(12.01M)(8.49M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":52.34,"profit":true},{"date":"2022-12-31","value":33.99,"profit":true},{"date":"2023-12-31","value":-27.24,"profit":false},{"date":"2024-12-31","value":-19.26,"profit":false}]
Income Taxes6.35M7.08M1.31M(1.46M)3.35M[{"date":"2020-12-31","value":89.64,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.54,"profit":true},{"date":"2023-12-31","value":-20.67,"profit":false},{"date":"2024-12-31","value":47.29,"profit":true}]
Income After Taxes37.75M16.00M13.67M(10.55M)(11.84M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.38,"profit":true},{"date":"2022-12-31","value":36.23,"profit":true},{"date":"2023-12-31","value":-27.94,"profit":false},{"date":"2024-12-31","value":-31.37,"profit":false}]
Income From Continuous Operations33.03M13.49M13.67M(10.55M)(11.84M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":40.83,"profit":true},{"date":"2022-12-31","value":41.39,"profit":true},{"date":"2023-12-31","value":-31.93,"profit":false},{"date":"2024-12-31","value":-35.84,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income37.75M16.00M13.67M(10.55M)(11.84M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.38,"profit":true},{"date":"2022-12-31","value":36.23,"profit":true},{"date":"2023-12-31","value":-27.94,"profit":false},{"date":"2024-12-31","value":-31.37,"profit":false}]
EPS (Diluted)0.160.220.46(0.20)(0.21)[{"date":"2020-12-31","value":33.74,"profit":true},{"date":"2021-12-31","value":48.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-42.52,"profit":false},{"date":"2024-12-31","value":-46.33,"profit":false}]

Pharming Group NV Ratios

Pharming Group NV Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

PHAR
Cash Ratio 1.89
Current Ratio 3.16
Quick Ratio 2.39

Pharming Group NV Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PHAR
ROA (LTM) 5.76%
ROE (LTM) 0.03%

Pharming Group NV Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PHAR
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.56

Pharming Group NV Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PHAR
Trailing PE NM
Forward PE 312.50
P/S (TTM) 2.97
P/B 4.03
Price/FCF 36
EV/R 2.94
EV/Ebitda 23.81

FAQs

What is Pharming Group NV share price today?

Pharming Group NV (PHAR) share price today is $16.866

Can Indians buy Pharming Group NV shares?

Yes, Indians can buy shares of Pharming Group NV (PHAR) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHAR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pharming Group NV be purchased?

Yes, you can purchase fractional shares of Pharming Group NV (PHAR) via the Vested app. You can start investing in Pharming Group NV (PHAR) with a minimum investment of $1.

How to invest in Pharming Group NV shares from India?

You can invest in shares of Pharming Group NV (PHAR) via Vested in three simple steps:

  • Click on Sign Up or Invest in PHAR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pharming Group NV shares
What is Pharming Group NV 52-week high and low stock price?

The 52-week high price of Pharming Group NV (PHAR) is $21.34. The 52-week low price of Pharming Group NV (PHAR) is $7.5.

What is Pharming Group NV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Pharming Group NV (PHAR) is

What is Pharming Group NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pharming Group NV (PHAR) is 4.03

What is Pharming Group NV dividend yield?

The dividend yield of Pharming Group NV (PHAR) is 0.00%

What is the Market Cap of Pharming Group NV?

The market capitalization of Pharming Group NV (PHAR) is $1.14B

What is Pharming Group NV's stock symbol?

The stock symbol (or ticker) of Pharming Group NV is PHAR

How Can Investors Use Pharming Group NV Share Price Data for Long-Term Investment Decisions?

Consider the share price of Pharming Group NV as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Pharming Group NV has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Pharming Group NV shares for Indian investors?

When investing in Pharming Group NV shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Pharming Group NV stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Pharming Group NV share price with other stocks in the same sector?

Rather than merely checking the share price of Pharming Group NV and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Pharming Group NV stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top